impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Burden of illness in fibromyalgia patients with comorbid depression

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Bateman Horne Center, Salt Lake City, UT, USA.
  2. Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy.
  3. Clinical Outcomes Solutions, Folkestone, Kent, UK.
  4. Pfizer Inc, Groton, CT, USA.
  5. Pfizer Inc, New York, NY, USA.
  6. Pfizer Inc, New York, NY, USA.
  7. Pfizer Inc, Groton, CT, USA.
  8. Pfizer Inc, Groton, CT, USA.
  9. Pfizer Inc, Louisville, KY, USA.
  10. Pfizer Inc, New York, NY, USA.
  11. Pfizer Inc, Groton, CT, USA. lynne.pauer@pfizer.com

CER8898
2016 Vol.34, N°2 ,Suppl.96
PI 0106, PF 0113
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27057659 [PubMed]

Received: 25/08/2015
Accepted : 08/02/2016
In Press: 10/03/2016
Published: 06/05/2016

Abstract

OBJECTIVES:
To assess the burden of fibromyalgia (FM) in patients with FM taking antidepressant medication for comorbid depression.
METHODS:
Symptom burden, impact on work and activity, and healthcare resource utilisation (HCRU) was examined at randomisation in patients enrolled in a clinical trial. Symptom burden was estimated based on self-reported health status measures. The Work Productivity and Activity Impairment: Specific Health Problem scale adapted to FM and a separate HCRU questionnaire were completed. The relationship between FM severity and burden was evaluated.
RESULTS:
The total population analysed comprised 193 patients; 71 (36.8%) had moderate FM and 119 (61.7%) severe FM. Patients had moderate pain, severe impairment in functioning due to FM, sleep disruption, mild anxiety, and mild depression. In the 7 days preceding randomisation, an average of 58.0% overall work impairment was reported, with 15.2% of working hours missed and 54.0% productivity while at work. In the 3 months preceding randomisation, on average, 5.0 visits per patient were made to healthcare professionals. Physical treatments were used by 34.7% and supplements by 31.6% of patients. Prescription and non-prescription medications, as well as professional services providing help with activities of daily living (ADL) that are impacted by FM, were used by >75% of patients. In addition, 50.4 hours of unpaid help was provided for ADL assistance. Total out-of-pocket expenditures were US$307.1, €410.4, or C$211.3, depending on location. FM burden worsened with increasing FM severity.
CONCLUSIONS:
This study demonstrates the significant burden of FM in patients with comorbid depression treated with an antidepressant.

Rheumatology Article